See more : AZZ Inc. (AZZ) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Playtech plc (PYTCF) Income Statement Analysis – Financial Results
- Tofas Türk Otomobil Fabrikasi Anonim Sirketi (TOASO.IS) Income Statement Analysis – Financial Results
- PTT Exploration and Production Public Company Limited (PTTEP.BK) Income Statement Analysis – Financial Results
- Regeneron Pharmaceuticals, Inc. (0R2M.L) Income Statement Analysis – Financial Results
- Brouwerij Handelsmaatschappij NV (COBH.BR) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
| Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
| Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
| General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
| Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
| SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
| Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
| Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
| Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
| Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
| Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
| EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
| EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
| Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
| Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
| Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
| EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:...
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024.
Source: https://incomestatements.info
Category: Stock Reports